Follow the progress of Hemolens Diagnostics
This website contains information intended only for persons professionally dealing with medical devices (e.g. for persons performing medical professions, for persons dealing with the distribution of medical devices). Please confirm that you are a medical device professional to proceed.
Follow the progress of Hemolens Diagnostics
March 20, 2023
Huawei Startup Academy is an initiative that was created for young, promising startups, offering them not only the opportunity to gain business expertise but also access to valuable contacts and financial support. In cooperation with Huawei Poland, it has been organizing the Huawei Startup Challenge competition for 3 years, where startups can present their ideas in front of experts and potential investors.
Huawei Startup Challenge is the third edition of the competition under the motto #TECHFORBETTERHEALTH. The competition is aimed at Polish startups that create solutions to improve our health – from prevention to control to treatment. In this year’s edition, one of the awarded startups is Hemolens Diagnostics.
In the Huawei Startup Academy competition, Hemolens Diagnostics was recognized for the innovation and market potential of its product. The jury also appreciated the experience and competence of the team that creates the startup.
Access to valuable contacts and financial support, thanks to recognition in the competition, can accelerate work on the implementation of diagnostic technology in the Polish market and entry into the European market.
Startups such as Hemolens Diagnostics are an important part of economic development. The innovative solutions they offer not only improve the quality of diagnosis and treatment but also influence the development of the entire medical industry.
It is important to note that in recent years many Polish startups have already gained recognition in international arenas, and the Polish startup market is growing dynamically. Initiatives such as the Huawei Startup Challenge play an essential role. Hemolens Diagnostics is a good example of how Polish innovative solutions, created by young companies and dynamic teams, can improve the quality of people’s lives and develop coronary artery disease diagnostics in Poland and around the world.
Photo. Startup Academy
June 23, 2023
Warsaw, 22 June 2023. – Wrocław-based Hemolens Diagnostics has been awarded this year’s “Polonica Progressio” award by the Minister...
June 21, 2023
Physical activity plays a key role in the prevention of cardiovascular disease and other cardiovascular disorders. Research shows that...
May 26, 2023
Wrocław, April 21, 2023. – Wrocław-based Hemolens Diagnostics has been recognized in this year’s Polish Product of the Future...
March 7, 2023
The Start-Up-Med competition is a prestigious initiative organized by PTWP Group (Polish Association for Entrepreneurship Support), publisher of, among...
March 1, 2023
Rebranding is a process aimed at changing one or more elements of a brand’s image communication. This includes changes...
February 24, 2023
The research project ‘HEMOFLOW cloud platform for non-invasive hemodynamic diagnostics’, No. POIR.01.01.01-00-0393/19, aims to assess the diagnostic value of...
January 11, 2023
What is FFR Measuring fractional flow reserve (FFR) is currently the ‘gold standard’ in the diagnostic assessment of coronary...
November 21, 2022
On 10 November at the ISPOR 2022 Europe conference, independent research company Panaxea presented the results of a study...
Cardiolens FFR-CT Pro is a coronary physiologic simulation software for the clinical quantitative and qualitative analysis of previously acquired Coronary Computed Tomography Angiography (CCTA) and optionally with Continuous Non-invasive Blood Pressure (CNBP) data for assessment of patients with suspected Chronic Coronary Syndromes (CCS). It provides hemodynamic diagnostic factor FFR-CT (Fractional Flow Reserve with Computed Tomography), a mathematically derived quantity, computed from simulated pressure, velocity and blood flow information obtained from a 3D computer model generated from static coronary CT images and optionally from CNBP measurement. The factor FFR-CT at the output of Cardiolens FFR-CT Pro device is intended to support the functional evaluation of coronary artery disease. The Cardiolens FFR-CT Pro outputs are provided to support qualified clinicians to aid in the evaluation and assessment of coronary arteries. The results of Cardiolens FFR-CT Pro are intended to be used by qualified clinicians in conjunction with the patient’s clinical history, symptoms, and other diagnostic tests, as well as the clinician’s professional judgment.